INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 65 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $0 | – | 959 | +6.8% | 0.00% | – |
| Q1 2023 | $0 | – | 898 | -4.6% | 0.00% | – |
| Q4 2022 | $0 | -100.0% | 941 | +4.0% | 0.00% | – |
| Q3 2022 | $1,000 | – | 905 | -20.8% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 1,143 | -78.7% | 0.00% | – |
| Q1 2022 | $6,000 | -86.7% | 5,378 | -72.7% | 0.00% | – |
| Q4 2021 | $45,000 | +32.4% | 19,684 | +99.7% | 0.00% | – |
| Q3 2021 | $34,000 | +88.9% | 9,858 | +62.7% | 0.00% | – |
| Q2 2021 | $18,000 | -60.0% | 6,060 | -56.9% | 0.00% | – |
| Q1 2021 | $45,000 | – | 14,055 | +5880.9% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 235 | -76.5% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 1,001 | -16.7% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 1,201 | +15.7% | 0.00% | – |
| Q1 2020 | $1,000 | – | 1,038 | +50.2% | 0.00% | – |
| Q4 2019 | $0 | -100.0% | 691 | -13.2% | 0.00% | – |
| Q3 2019 | $1,000 | – | 796 | +298.0% | 0.00% | – |
| Q2 2019 | $0 | – | 200 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 200 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 200 | -36.3% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 314 | -55.1% | 0.00% | – |
| Q2 2018 | $1,000 | – | 700 | +208.4% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 227 | -84.9% | 0.00% | – |
| Q3 2017 | $2,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | -81.8% | 1,500 | -58.6% | 0.00% | – |
| Q1 2017 | $11,000 | +83.3% | 3,621 | -24.8% | 0.00% | – |
| Q4 2016 | $6,000 | +200.0% | 4,818 | +198.1% | 0.00% | – |
| Q3 2016 | $2,000 | 0.0% | 1,616 | 0.0% | 0.00% | – |
| Q2 2016 | $2,000 | -99.1% | 1,616 | -91.7% | 0.00% | – |
| Q2 2015 | $212,000 | +175.3% | 19,418 | +253.1% | 0.00% | – |
| Q1 2015 | $77,000 | -88.8% | 5,500 | -86.4% | 0.00% | – |
| Q4 2014 | $685,000 | +35.9% | 40,567 | +8.0% | 0.00% | – |
| Q3 2014 | $504,000 | +4.3% | 37,567 | -1.1% | 0.00% | – |
| Q2 2014 | $483,000 | +580.3% | 37,967 | +538.1% | 0.00% | – |
| Q1 2014 | $71,000 | -2.7% | 5,950 | +13.3% | 0.00% | – |
| Q4 2013 | $73,000 | +58.7% | 5,250 | +97.2% | 0.00% | – |
| Q3 2013 | $46,000 | -94.6% | 2,662 | -95.0% | 0.00% | -100.0% |
| Q2 2013 | $855,000 | – | 52,817 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |